Arbutus Biopharma (ABUS) Tops Q1 EPS by 91c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of $0.87, $0.91 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $179.23 million versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Westinghouse said to seek over $50 billion valuation in planned IPO
• Anthropic delays planned IPO from October to November - WSJ